SGS, a testing, inspection, and certification company, has partnered with Berlin-based startup theblood to support the development and validation of diagnostics based on menstrual blood.
SGS will serve as an independent quality and validation partner, contributing bioanalytical expertise as theblood explores menstrual blood as a diagnostic matrix. The partnership aims to establish scientific and regulatory foundations for this emerging area of diagnostics.
Menstrual blood contains biomarkers that could be relevant for health monitoring, particularly for inflammatory-related disorders such as endometriosis, PCOS, and other fertility-related conditions. However, medical applications require validation to establish accuracy and reproducibility.
“Innovative diagnostics only gain relevance when they are supported by scientific credibility and quality,” said Dr Dr Sheida Hoenlinger, Director of Business Development at SGS in Austria. “Through this partnership, we are accompanying the responsible development of a new matrix and its path toward trusted applications.”
Isabelle Guenou, Founder and CEO of theblood, said: “With SGS accompanying this journey, we are ensuring that the exploration of menstrual blood is guided by scientific rigor, quality and long-term trust.”
theblood focuses on developing non-invasive diagnostics from menstrual blood across fertility, menopause, hormonal balance, and inflammatory conditions. SGS is headquartered in Switzerland and operates over 2,500 laboratories across 115 countries.
